Newquay based Green Park Pharma has secured £500,000 equity funding from the British Business Bank’s South West Investment Fund via appointed Fund Manager, The FSE Group, as part of a £2.2million pre-series A funding round with the option for a further £4.5m investment in later rounds.
Green Park Pharma specialises in developing liquid formulations of existing medications. The company's patented technology provides solutions for the currently unmet clinical needs of an estimated 20-40% of patients globally who struggle to swallow tablets.
Developing a liquid formulation from a solid medication is traditionally done by a pharmacist, reconstituting medicines from dried powder, but these liquid forms have a limited shelf life and often need refrigeration. Green Park Pharma’s advanced technology can create equivalent products in a stable, ready-to-use liquid form that is fully licensed, and patent protected.
Richard Reavley, Green Park Pharma Group CEO said: “Difficulty taking tablets is a common problem in paediatrics but extends to adults experiencing swallow impairment, including those suffering from serious conditions such as stroke, dementia and some forms of cancer. Our liquid products are effective and stable at room temperature with a long shelf life, improving medication adherence, dosage accuracy and convenience for the NHS, patients, and caregivers. We are thrilled to receive this investment, which will help us make a significant impact on the global pharmaceutical landscape.”
The investment will enable Green Park Pharma to expand its operations and workforce, with plans to create ten new roles over the next three years as part of its strategy to enhance global reach and operational capabilities.
Anna Staevska, Investment Manager at The FSE Group, commented: “Green Park Pharma's robust business model and patented technology present a unique opportunity that we’re excited to be a part of. The secured funding positions the company well for rapid development and market penetration and we look forward to working with them on this journey.”
Paul Jones, Senior Investment Manager, British Business Bank said: “Green Park Pharma is an excellent example of an innovative, high-growth business that the South West Investment Fund was created to support. Their liquid-based medicines address a clear clinical need for alternative drug delivery and this investment reflects our commitment to increasing access to equity finance for ambitious businesses across the region.”
Green Park Pharma is led by industry veterans with extensive experience in pharmaceuticals, product development, and strategic partnerships. With a proven track record of launching over 40 products globally, the team is committed to delivering innovative healthcare solutions and well-equipped to drive the company's ambitious growth plans.
The purpose of the South West Investment Fund is to drive sustainable economic growth by supporting innovation and creating local opportunity for new and growing businesses across the South West. It offers a range of commercial finance options with smaller loans from £25k to £100k, debt finance from £100k to £2m and equity investment up to £5 million.
The fund is increasing the supply and diversity of early-stage finance for South West smaller businesses, providing funds to firms that might otherwise not receive investment and helping to break down barriers in access to finance.